W. Beau Mitchell
New York Blood Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by W. Beau Mitchell.
Transfusion | 2012
Mauro P. Avanzi; Amanda Chen; Wu He; W. Beau Mitchell
BACKGROUND: Large‐scale in vitro production of platelets (PLTs) from cord blood stem cells is one goal of stem cell research. One step toward this goal will be to produce polyploid megakaryocytes capable of releasing high numbers of PLTs. Megakaryocyte polyploidization requires distinct cytoskeletal and cellular mechanisms, including actin polymerization, myosin activation, microtubule formation, and increased DNA production. In this study we variably combined inhibition of these principal mechanisms of cytokinesis with the goal of driving polyploidization in megakaryocytes.
Haematologica | 2016
Emmanuelle Godefroy; Yunfeng Liu; Patricia Shi; W. Beau Mitchell; Devin Cohen; Stella T. Chou; Deepa Manwani; Karina Yazdanbakhsh
Transfusions are the main treatment for patients with sickle cell disease. However, alloimmunization remains a major life-threatening complication for these patients, but the mechanism underlying pathogenesis of alloimmunization is not known. Given the chronic hemolytic state characteristic of sickle cell disease, resulting in release of free heme and activation of inflammatory cascades, we tested the hypothesis that anti-inflammatory response to heme is compromised in alloimmunized sickle patients, increasing their risk of alloimmunization. Heme-exposed monocyte-derived dendritic cells from both non-alloimmunized sickle patients and healthy donors inhibited priming of pro-inflammatory CD4+ type 1 T cells, and exhibited significantly reduced levels of the maturation marker CD83. In contrast, in alloimmunized patients, heme did not reverse priming of pro-inflammatory CD4+ cells by monocyte-derived dendritic cells or their maturation. Furthermore, heme dampened NF-κB activation in non-alloimmunized, but not in alloimmunized monocyte-derived dendritic cells. Heme-mediated CD83 inhibition depended on Toll-like receptor 4 but not heme oxygenase 1. These data suggest that extracellular heme limits CD83 expression on dendritic cells in non-alloimmunized sickle patients through a Toll-like receptor 4-mediated pathway, involving NF-κB, resulting in dampening of pro-inflammatory responses, but that in alloimmunized patients this pathway is defective. This opens up the possibility of developing new therapeutic strategies to prevent sickle cell alloimmunization.
Transfusion | 2016
Aabhas Mathur; Raquibul Chowdhury; Christopher D. Hillyer; W. Beau Mitchell; Beth H. Shaz
Each unit of blood donated is processed and stored individually resulting in variability in the amount of red blood cells (RBCs) collected, RBC properties, and the 24‐hour posttransfusion RBC survivability. As a result, each unit differs in its ability to deliver oxygen and potentially its effects on the recipient. The goal of this study was to investigate the storage of pooled RBCs from multiple donors in comparison to control standard RBC units.
Archive | 2012
W. Beau Mitchell; Mauro P. Avanzi
Blood | 2011
W. Beau Mitchell; Merlin Nithya Gnanapragasam; Julie Jaffray; James J. Bieker; Deepa Manwani
Archive | 2009
W. Beau Mitchell; Mahmoud Yazdani Abyaneh; Amanda Chen
Blood | 2013
Emily Leven; Michelle A. Berny-Lang; Hannah Tamary; Shoshana Revel-Vilk; Sabrina L. Carmichael; W. Beau Mitchell; Alan D. Michelson; James B. Bussel
Blood | 2010
W. Beau Mitchell; Michele N. Edison; Mariana P Pinheiro; Nayla Boulad; Bethan Psaila; Marissa Karpoff; David L. Kaplan; Benjamin T. Kile; Michael J. White; Emma C. Josefsson; James B. Bussel
Blood | 2015
Emmanuelle Godefroy; Yunfeng Liu; Patricia Shi; W. Beau Mitchell; Devin Cohen; Stella T. Chou; Deepa Manwani; Karina Yazdanbakhsh
Blood | 2013
Oluwasijibomi E. Oluwadara; W. Beau Mitchell